Zealand Pharma initiated with an Equal Weight at Morgan Stanley

Morgan Stanley initiated coverage of Zealand Pharma (ZLDPF) with an Equal Weight rating and DKK 755 price target The company’s next major catalyst is a petrelintide partnership, but there is limited visibility on the timing and terms, the analyst tells investors in a research note.